Human Genome Epidemiology Literature Finder
|
Records 1 - 9 (of 9 Records) |
| Query Trace: Fibrosis and CYP2D6[original query] |
|---|
| Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver 2006 Apr 26 (3): 279-84. Fishman Sigal, Lurie Yoav, Peretz Hava, Morad Tova, Grynberg Elisheva, Blendis Laurie M, Leshno Moshe, Brazowski Eli, Rosner Guy, Halpern Zamir, Oren R |
| The recipient CYP2D6 allele 4-associated poor metabolizer status correlates with an early fibrosis development after liver transplantation. Transplant international : official journal of the European Society for Organ Transplantation 2011 Nov 24 (11): 1059-67. Zimmermann Tim, Hoppe-Lotichius Maria, Körner Andreas, Lautem Anja, Heise Michael, Foltys Daniel, Weiler Nina, Biesterfeld Stefan, Schmidtmann Irene, Galle Peter R, Otto Gerd, Schuchmann Marc |
| Cytochrome P450 2D6 polymorphism is a molecular genetic marker of liver cirrhosis progression. Bulletin of experimental biology and medicine 2012 Mar 152 (5): 633-6. Nepomnyashchikh D L, Vavilin V A, Aidagulova S V, Makarova S I, Karavaeva Yu Yu, Shchepotina E G, Postnikova O A, Nokhrina Zh V, Vinogradova E V, Lyakhovich V |
| Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Oncotarget 2016 May . Zhou Jun, Wen Qiang, Li Sai-Fei, Zhang Yun-Fei, Gao Na, Tian Xin, Fang Yan, Gao Jie, Cui Ming-Zhu, He Xiao-Pei, Jia Lin-Jing, Jin Han, Qiao Hai-Li |
| Impact of CYP2D6 Polymorphisms on Tamoxifen Treatment in Patients With Retroperitoneal Fibrosis: A First Step Towards Tailored Therapy? Urology 2019 Dec . Dreger Nici Markus, Degener Stephan, Roth Stephan, Ahmad-Nejad Parviz, Kamper Lars, Müller Elisabeth, von Rundstedt Friedrich Carl, Brandt Alexander Sasc |
| Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis. Biomedicines 2022 May 10 (5): . Zyryanov Sergey K, Ushkalova Elena A, Kondratyeva Elena I, Butranova Olga I, Kondakova Yulia |
| No drug-drug interactions between selective prolyl-trna synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants. Clinical and translational science 2023 12 . Wonsuk Shin, Min Young Park, Jongwoo Kim, Jihyeon Kim, Jun Hee Nam, Jongwon Choi, A-Young Yang, Hyounggyoon Yoo, Yil-Seob Lee, Anhye K |
| Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2024 6 . Anindit Chhibber, Alexandre Hikiji Watanabe, Hollyann Jacobs, Aditi Kharat, Sakil M Syeed, Catherine M Sherwin, Nathorn Chaiyakunapruk, Joseph Biskupiak, Venkata K Yellepeddi, Diana Brixner, David C You |
| Predictors of Selective Serotonin Reuptake Inhibitor Treatment Failure in Persons With Cystic Fibrosis. Pediatric pulmonology 2024 11 . Rebecca S Pettit, Coleen M Sakon, Kaitlyn E Kinney, Cynthia Brown, Katherine A Gallaway, Sarah A Wagner, Emma M Tillm |
- Page last reviewed:Feb 1, 2024
- Content source: